Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average Target Price from Brokerages

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been assigned an average rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $3.33.

A number of research firms recently weighed in on SYRS. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com began coverage on Syros Pharmaceuticals in a report on Tuesday. They issued a “sell” rating on the stock. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new stake in Syros Pharmaceuticals in the 4th quarter valued at approximately $25,000. Exome Asset Management LLC lifted its stake in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Trading Down 6.0 %

NASDAQ SYRS opened at $0.14 on Friday. The stock has a market capitalization of $3.87 million, a price-to-earnings ratio of -0.05 and a beta of 1.30. The business’s 50 day moving average is $0.20 and its two-hundred day moving average is $1.05. Syros Pharmaceuticals has a 12-month low of $0.14 and a 12-month high of $7.90.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.